Cryopreservation of sperm from adolescents and adults with malignancies.

Melatonin and testicular damage in busulfan treated mice. Iran Red Crescent Med J (2014) 0.81

Evidence-Based Recommendations for Fertility Preservation Options for Inclusion in Treatment Protocols for Pediatric and Adolescent Patients Diagnosed With Cancer. J Pediatr Oncol Nurs (2014) 0.81

Does prepubertal testicular tissue vitrification influence spermatogonial stem cells (SSCs) viability? J Assist Reprod Genet (2013) 0.77

Cryopreservation of testis tissues and in vitro spermatogenesis. Reprod Med Biol (2015) 0.76

Effect of Melatonin on the Expression of Apoptotic Genes in Vitrified-thawed Spermatogonia Stem Cells Type A of 6-Day-Old Mice. Iran J Basic Med Sci (2013) 0.76

Cryopreservation of sperm from adolescents and adults with malignancies. J Urol (2005) 0.75

MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90

Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater (2011) 3.83

Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29

Klinefelter's syndrome. Lancet (2004) 2.89

The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol (2011) 2.79

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood (2004) 2.77

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet (2010) 2.62

Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood (2009) 2.54

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol (2008) 2.54

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46

Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell (2009) 2.39

Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol (2005) 2.36

Clinical and diagnostic features of patients with suspected Klinefelter syndrome. J Androl (2003) 2.29

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol (2006) 2.22

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol (2008) 2.01

Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood (2007) 1.99

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol (2012) 1.91

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res (2003) 1.87

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood (2007) 1.84

Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood (2007) 1.81

Gene polymorphisms and male infertility--a meta-analysis and literature review. Reprod Biomed Online (2007) 1.79

Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab (2008) 1.79

Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab (2006) 1.78

Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol (2009) 1.73

Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood (2011) 1.73

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood (2005) 1.69

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood (2002) 1.68

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood (2002) 1.68

Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica (2006) 1.64

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60

Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol (2005) 1.59

Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis. Eur Urol (2013) 1.59

Ten years' experience with an external quality control program for semen analysis. Fertil Steril (2012) 1.57

Reproductive functions of the ageing male. Hum Reprod Update (2004) 1.57

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res (2005) 1.51

High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res (2004) 1.50

ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol (2009) 1.48

Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J Urol (2006) 1.47

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 1.46

The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43

Fertility control in wildlife: humans as a model. Contraception (2005) 1.43

S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res (2004) 1.41

Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis. Urology (2005) 1.40

Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer (2008) 1.39

Paternal age and reproduction. Hum Reprod Update (2009) 1.36

Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab (2007) 1.36

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol (2008) 1.35

Long-term results of amitriptyline treatment for interstitial cystitis. J Urol (2005) 1.31

Clinical, endocrinological, and epigenetic features of the 46,XX male syndrome, compared with 47,XXY Klinefelter patients. J Clin Endocrinol Metab (2007) 1.30

Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood (2007) 1.28

Workflow to improve patient recruitment for clinical trials within hospital information systems - a case-study. Trials (2008) 1.27

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol (2012) 1.27

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood (2003) 1.23

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol (2007) 1.22

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood (2012) 1.22

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res (2005) 1.22

A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol (2004) 1.22

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol (2008) 1.21

Osteosarcoma: the COSS experience. Cancer Treat Res (2009) 1.18

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol (2003) 1.18

Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer (2005) 1.17

Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood (2005) 1.16

DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res (2007) 1.15

RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood (2004) 1.15

Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) (2004) 1.14

Clinical consequences of microdeletions of the Y chromosome: the extended Münster experience. Reprod Biomed Online (2008) 1.13

Identification of acute myeloid leukaemia associated microRNA expression patterns. Br J Haematol (2008) 1.13

Wnt signaling regulates transendothelial migration of monocytes. J Leukoc Biol (2006) 1.12

Signal transduction of oncogenic Flt3. Int J Hematol (2005) 1.12

Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood (2007) 1.12

ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male (2009) 1.11

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood (2010) 1.11

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood (2009) 1.10

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer (2006) 1.09

The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Clin Cancer Res (2010) 1.09

S100A2 induces metastasis in non-small cell lung cancer. Clin Cancer Res (2009) 1.09

Minutes of the 14th European workshop on molecular and cellular endocrinology of the testis. Mol Cell Endocrinol (2006) 1.08

Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res (2004) 1.07

Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr Drug Targets (2007) 1.07

Identification of interaction partners and substrates of the cyclin A1-CDK2 complex. J Biol Chem (2004) 1.06

Follicle-stimulating hormone receptor polymorphisms in women with normogonadotropic anovulatory infertility. Fertil Steril (2003) 1.06

Single-nucleotide polymorphisms in the promoter region influence the expression of the human follicle-stimulating hormone receptor. Fertil Steril (2005) 1.06

Role of sequence variations of the GnRH receptor and G protein-coupled receptor 54 gene in male idiopathic hypogonadotropic hypogonadism. Eur J Endocrinol (2005) 1.06

RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica (2012) 1.06

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood (2009) 1.05

Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab (2008) 1.05

Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogene (2005) 1.04

The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl (2003) 1.04

Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica (2003) 1.03

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet (2005) 1.03

Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics (2005) 1.02

Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol (2002) 1.02

Cytoplasmic droplets are normal structures of human sperm but are not well preserved by routine procedures for assessing sperm morphology. Hum Reprod (2004) 1.01

Is human fecundity declining in Western countries? Hum Reprod (2010) 1.01

Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology (2007) 1.00